CoChat

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Open access

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide for the treatment of patients with type 2 diabetes mellitus (T2DM). The present study evaluated pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with T2DM. METHODS: Canagliflozin, at doses of 25, 100, 200, or 400 mg, was administered as a single dose and, after a washout of 1 day, in repeated doses for 14 consecutive days to 61 subjects in a randomized, double-blind, placebo-controlled study. Plasma concentrations of canagliflozin and urinary glucose excretion (UGE) were measured, and renal threshold for glucose excretion (RTG) was calculated. Safety was evaluated on the basis of adverse event (AE) reports, blood and urine laboratory parameters, and vital signs. RESULTS: Plasma canagliflozin maximum concentration and area under the concentration-time curve (AUC) values increased in a dose-dependent manner with the time to maximum concentration (t max) of 1.0 h and elimination half-life (t 1/2) of 10.22-13.26 h on Day 1. No significant changes in t max and t 1/2 were observed after multiple-dose administration. The linearity factors, as calculated from the ratios of AUC0-24h on Day 16 to AUC0-∞ on Day 1, were close to 1 in all canagliflozin groups. Canagliflozin increased UGE0-24h (80-110 g/day with canagliflozin ≥100 mg) and decreased RTG from the first day of treatment; these effects were sustained during the entire period of multiple administration. No significant AEs were noted. Urine volume was slightly increased on Day 1, but subsequent changes after repeated doses for 14 days were small. Urinary sodium tended to be higher in the early treatment period, whereas no particular change was observed in serum osmolality and hematocrit. CONCLUSION: Canagliflozin increased UGE, decreased RTG, and was well tolerated throughout the entire period of multiple administrations in Japanese patients with T2DM. FUNDING: Mitsubishi Tanabe Pharma Corporation. TRIAL REGISTRATION: ClinicalTrials.gov#NCT00707954.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-015-0234-0

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design (a) and participant flow (b)
Fig. 1 Study design (a) and participant flow (b)CC BY-NC · PubMed Central
Fig. 2 Plasma concentration–time profiles after canagliflozin treatment on Days 1 and 16. Data are presented as the mean ± standard deviation
Fig. 2 Plasma concentration–time profiles after canagliflozin treatment on Days 1 and 16. Data are presented as the mean ± standard deviationCC BY-NC · PubMed Central
Fig. 3 Effect of canagliflozin on changes in 24-h UGE (a) and 24-h mean RTG (b). Data are mean ± standard deviation. UGE urinary glucose excretion, RT G renal threshold for glucose
Fig. 3 Effect of canagliflozin on changes in 24-h UGE (a) and 24-h mean RTG (b). Data are mean ± standard deviation. UGE urinary glucose excretion, RT G renal threshold for glucoseCC BY-NC · PubMed Central
Fig. 4 Effects of canagliflozin on the changes from baseline in urinary volume (a), water intake (b), and urinary sodium excretion (c). Data are mean ± standard deviation
Fig. 4 Effects of canagliflozin on the changes from baseline in urinary volume (a), water intake (b), and urinary sodium excretion (c). Data are mean ± standard deviationCC BY-NC · PubMed Central
Fig. 5 Change from baseline on Day 1 in urine volume (a), sodium excretion (b), and urine osmolality (c). Data are mean ± standard deviation
Fig. 5 Change from baseline on Day 1 in urine volume (a), sodium excretion (b), and urine osmolality (c). Data are mean ± standard deviationCC BY-NC · PubMed Central
Fig. 6 Effects of canagliflozin on serum osmolality (a) and hematocrit (b). Data are mean ± standard deviation
Fig. 6 Effects of canagliflozin on serum osmolality (a) and hematocrit (b). Data are mean ± standard deviationCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 70

Metadata

Authors
Iijima, H., Kifuji, T., Maruyama, N., & Inagaki, N.
Affiliations
  • Tanabe Pharma Corporation (Japan) (JP)
  • Kyoto University (JP)
Corresponding author
Iijima, Hiroaki
Venue
Advances in Therapy
Published
2015-08
Volume
32
Issue
8
Pages
768-782
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W1867144247
Cited by
70
References
30
Citations by year
2026: 5 · 2025: 9 · 2024: 6 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 10 · 2019: 4 · 2018: 6 · 2017: 2 · 2016: 4
FWCI
3.47
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Mitsubishi Tanabe Pharma Corporation
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
canagliflozin, SGLT2 inhibitors, type 2 diabetes, pharmacokinetics, pharmacodynamics, urinary glucose excretion, renal glucose threshold, repeated dosing, drug safety, Japanese patients, dose dependence, adverse events, urinary sodium, serum osmolality, hematocrit, urine output, elimination half-life, bioavailability
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Half-Life, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Drug Monitoring, Asian People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1007/s12325-015-0234-0
The paper
Iijima, H., Kifuji, T., Maruyama, N., & Inagaki, N. (2015). Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy. https://doi.org/10.1007/s12325-015-0234-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.